Evidence map›Paper›PMID 36129879›Full record

ArticlePloS one2022

Epidemiology and risk factors related to severity of clinical manifestations of COVID-19 in outpatients: A retrospective study in Haiti.

Mentor Ali Ber Lucien, Katilla Pierre, Gladzdin Jean-Denis, Jonas Rigodon, Caitlin M Worrell, Alexia Couture, Aspen Flynn, Mauricio Cerpa Calderon, Luis Felipe Codina, Andrea S Vicari and 15 more

Abstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Mentor Ali Ber LucienNational Public Health Laboratory (LNSP)/ Ministry of Public Health and Population (MSPP), Port au Prince, Haiti.
Katilla PierreDirectorate of Epidemiology, Laboratories and Research (DELR)/MSPP, Port au Prince, Haiti.
Gladzdin Jean-DenisPan American Health Organization, World Health Organization (PAHO/WHO), Port-au-Prince, Haiti.
Jonas RigodonU.S. Centers for Disease Control and Prevention, Port-au-Prince, Haiti.ORCID 0000-0002-6181-9998
Caitlin M WorrellDivision of Parasitic Diseases and Malaria, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.ORCID 0000-0003-0229-6565
Alexia CoutureCOVID-19 International Task Force Emergency Response Capacity Team, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.ORCID 0000-0002-4257-3697
Aspen FlynnCOVID-19 International Task Force Emergency Response Capacity Team, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America.
Mauricio Cerpa CalderonPan American Health Organization, World Health Organization (PAHO/WHO), Port-au-Prince, Haiti.
Luis Felipe CodinaPan American Health Organization, World Health Organization (PAHO/WHO), Port-au-Prince, Haiti.
Andrea S VicariPan American Health Organization, World Health Organization (PAHO/WHO), Washington, DC, United States of America.
Samson MarseilleDirectorate of Epidemiology, Laboratories and Research (DELR)/MSPP, Port au Prince, Haiti.
Koama T Jean BaptisteU.S. Centers for Disease Control and Prevention, Port-au-Prince, Haiti.
Bernadette FoucheQuisqueya University, Port-au-Prince, Haiti.ORCID 0000-0002-6667-9963
Gerard JosephNational Public Health Laboratory (LNSP)/ Ministry of Public Health and Population (MSPP), Port au Prince, Haiti.
Ito JournelNational Public Health Laboratory (LNSP)/ Ministry of Public Health and Population (MSPP), Port au Prince, Haiti.
Kenold RendelDirectorate of Epidemiology, Laboratories and Research (DELR)/MSPP, Port au Prince, Haiti.
Yoran Grant-GreeneU.S. Centers for Disease Control and Prevention, Port-au-Prince, Haiti.
Nadia P Jean-CharlesU.S. Centers for Disease Control and Prevention, Port-au-Prince, Haiti.
Donald LafontantDirectorate of Epidemiology, Laboratories and Research (DELR)/MSPP, Port au Prince, Haiti.
Senou AmouzouDirectorate of Epidemiology, Laboratories and Research (DELR)/MSPP, Port au Prince, Haiti.
Wilnique PierreDirectorate of Epidemiology, Laboratories and Research (DELR)/MSPP, Port au Prince, Haiti.
Marie Greta Roy ClementMinistry of Public Health and Population (MSPP), Port au Prince, Haiti.
Stanley JuinU.S. Centers for Disease Control and Prevention, Port-au-Prince, Haiti.
Jacques BoncyNational Public Health Laboratory (LNSP)/ Ministry of Public Health and Population (MSPP), Port au Prince, Haiti.
Patrick DelyDirectorate of Epidemiology, Laboratories and Research (DELR)/MSPP, Port au Prince, Haiti.

Funding

World Health Organization 001
6 · The paper itself

Abstract

backgroundHaiti's first COVID-19 cases were confirmed on March 18, 2020, and subsequently spread throughout the country. The objective of this study was to describe clinical manifestations of COVID-19 in Haitian outpatients and to identify risk factors for severity of clinical manifestations.

methodsWe conducted a retrospective study of COVID-19 outpatients diagnosed from March 18-August 4, 2020, using demographic, epidemiological, and clinical data reported to the Ministry of Health (MoH). We used univariate and multivariate analysis, including multivariable logistic regression, to explore the risk factors and specific symptoms related to persons with symptomatic COVID-19 and the severity of symptomatic COVID-19 disease.

resultsOf 5,389 cases reported to MOH during the study period, 1,754 (32.5%) were asymptomatic. Amongst symptomatic persons 2,747 (75.6%) had mild COVID-19 and 888 (24.4%) had moderate-to-severe disease; the most common symptoms were fever (69.6%), cough (51.9%), and myalgia (45.8%). The odds of having moderate-to-severe disease were highest among persons with hypertension (aOR = 1.72, 95% Confidence Interval [CI] (1.34, 2.20), chronic pulmonary disease (aOR = 3.93, 95% CI (1.93, 8.17)) and tuberculosis (aOR = 3.44, 95% CI (1.35, 9.14)) compared to persons without those conditions. The odds of having moderate-to-severe disease increased with age but was also seen among children aged 0-4 years (OR: 1.73, 95% CI (0.93, 3.08)), when using 30-39 years old as the reference group. All of the older age groups, 50-64 years, 65-74 years, 75-84 years, and 85+ years, had significantly higher odds of having moderate-to-severe COVID-19 compared with ages 30-39 years. Diabetes was associated with elevated odds of moderate-to-severe disease in bivariate analysis (OR = 2.17, 95% CI (1.58,2.98) but, this association did not hold in multivariable analyses (aOR = 1.22,95%CI (0.86,1.72)).

conclusionThese findings from a resource-constrained country highlight the importance of surveillance systems to track emerging infections and their risk factors. In addition to co-morbidities described elsewhere, tuberculosis was a risk factor for moderate-to-severe COVID-19 disease.

Indexed as

COVID-19AdultAgedChildHaitiHumansOutpatientsRetrospective StudiesRisk FactorsSARS-CoV-2

Identifiers

PMID36129879
PMCPMC9491605

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.